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Abstract
Background: In endemic area, nasopharyngeal carcinoma (NPC) tumor cells harbor EBV latent infection and expresses
viral antigens such as EBNA1, LMP1 and LMP2. In this study, we established a NPC-mimicry animal model and assessed
the therapeutic potential of LMP1 vaccine.
Methods: Animal models were established by injection of LMP1-expressing TC-1 cells in C57BL6/J mice subcutaneously
or through tail veins. pcDNA3.1 empty vector or LMP1/pcDNA3.1 vaccine was delivered by a helium-driven gene gun.
Effectiveness of vaccine was evaluated by measuring the tumor size and numbers of metastatic lung nodules. Circulating
cytokines were evaluated by ELISArray. Populations of activated cytotoxic T lymphocytes (CTLs) and LMP1-
specific T lymphocytes were evaluated by flow cytometry with CD8/CD107a double staining and interferon-γ
ELISPOT assay, respectively.
Results: LMP1 vaccine significantly suppressed tumor growth (n = 3) and metastasis (n = 4) in vivo. When vaccinated
before tumor challenge, all mice in vaccine group were tumor-free, whereas all mice in the control group developed
tumors within 2 weeks after tumor challenge (n = 10). Cytokine ELISArray revealed elevation of a panel of
proinflammatory cytokines in mice receiving LMP1 vaccine. Flow cytometry and interferon-γ ELISPOT assay
revealed that LMP1 vaccine induced larger populations of activated CTLs and LMP1-specific T lymphocytes.
Conclusions: This pre-clinical study provides a promising result that LMP1 vaccine suppresses LMP1-expressing tumor
growth and metastasis in vivo.
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Background
Epstein-Barr virus (EBV), a member of the herpesvirus
family, was the first virus identified to correlate with
human malignancies such as Hodgkin’s disease (HD),
Burkitt’s lymphoma, nasopharyngeal carcinoma (NPC)
and gastric carcinoma [1]. Different from other type of
cancers, virus-associated malignancies express foreign
epitopes by major histocompatibility complex (MHC)
molecules, which can be recognized by cytotoxic T lym-
phocytes (CTLs). Therefore, immunogenicity of latent
viral proteins and strategies to activate antigen-specific
CTLs has become the focus of immunotherapies against
virus-associated malignancies in recent decades [2].
NPC arises from epithelia of the nasopharynx and al-
most all tumors in the endemic area including Southern
and South-Eastern Asia, are associated with EBV infection
[3]. The mortality rate of NPC has been decreasing in the
past two decades owing to advances to multidisciplinary
treatment including radiation and combination chemo-
therapy. However, the failure to treat locally-aggressive
* Correspondence: thyoung@ntu.edu.tw; pjlou@ntu.edu.tw
3Institute of Biomedical Engineering, College of Medicine and College of
Engineering, National Taiwan University, No. 1, Sec. 1, Jen-Ai Road, Taipei
100, Taiwan
2Graduate Institute of Anatomy and Cell Biology, National Taiwan University
College of Medicine, No. 1, Sec. 1, Jen-Ai Road, Taipei 100, Taiwan
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Lin et al. BMC Cancer  (2017) 17:18 
DOI 10.1186/s12885-016-3027-1
nasopharyngeal carcinoma is not uncommon and distant
metastases remains the main cause of death [4]. The
strong association of NPC with EBV makes viral antigen-
targeted immunotherapy an attractive treatment modality
[5]. Adoptive transfer of autologous EBV-specific CTL has
proven effective in metastatic or locally recurrent NPC
patients [6]. Meanwhile, efficacies of DNA vaccines
carrying various combination of EBV antigens are also
under evaluation [7–9].
NPC, as well as HD, represents the classic type II latent
infection by the expression of EBV nuclear antigen 1
(EBNA1), latent membrane proteins (LMP) 1 and 2 [10].
EBNA1 evades CTL recognition by blocking MHC com-
plex I epitopes presentation [11, 12]. However, LMP1 and
LMP2 are relatively immunogenic and have been pro-
posed as therapeutic targets [13, 14]. In this study, we
establish a NPC-mimicry animal model and demonstrate
that LMP1 encoding DNA vaccine is effective in tumor
suppression and prevention. In addition, we also show
that LMP1 vaccine successfully induces elevation of proin-
flammatory cytokines and activates LMP1-specific CTLs.
Taken together, these results support the implication of
LMP1-based DNA vaccine in clinical use in the future.
Methods
Cell culture
Mus musculus lung tumor cell line, TC-1, was kindly
provided by Dr. Wen-Fang Cheng (National Taiwan
University Hospital) [15] and cultured in RPMI-1640
(Invitrogen) supplemented with 10% fetal bovine serum
(FBS, PAA laboratories), 50 U/mL of penicillin/strepto-
mycin, 2 mM of L-glutamine, 1 mM of sodium pyruvate,
2 mM of non-essential amino acids and 0.4 mg/mL of
G418 (Sigma-Aldrich) at 37 °C with 5% CO2.
Plasmid construction
Primary NPC tissues were obtained with inform consents
from patients (IRB number: 201304078RIND). Total RNA
was extracted from primary NPC tissues with TRIzol®
Reagent (Invitrogen) according to the manufacturer’s
protocol. Reverse transcription reaction was performed
using the Superscript III First-Strand cDNA Synthesis Kit
(Invitrogen) with 2 μg of total RNA. LMP1 was obtained
by real-time RT-PCR with the following primers, 5′-ggat
ccgccatggaacacgaccttgagaggggcccac-3′ and 5′-gcggccgctc
atagtagcttagctgaactgggccgtg-3′. LMP1 was subcloned into
pLenti6/V5-DEST with BamHI and NotI as restriction
sites. Lentivirus expression system was carried out ac-
cording to the manufacturer’s protocol (Invitrogen).
Stable Mock (pLenti6/V5-DEST) or LMP1 (LMP1/
pLenti6/V5-DEST) TC-1 clones were selected with
3 μg/mL blasticidin (Invitrogen). For generation of
DNA vaccine, the CRT/pcDNA3.1 vector was a gift
from Dr. Wen-Fang Cheng [15]. LMP1 was cloned
from LMP1/pLenti6/V5-DEST with the following primers,
5′-gaattcatggaacacgaccttgagag-3′, 5′-aagcttttagtcatagtagct
tagct-3′ and subcloned into CRT/pcDNA3.1 vectors using
the restriction site of EcoRI and HindIII. All constructs
were verified by DNA sequencing.
Western blot analysis
Cell pellets were homogenized in lysis buffer containing 1%
Triton X-100, 20 mM Tris-HCl, pH 8.0, 160 mM NaCl,
1 mM CaCl2, and 1 mM phenylmethysulfonyl fluoride.
Insoluble material was removed by centrifugation at
14,000 rpm for 15 min. Cell lysates were boiled at 95 °C for
5 min in SDS-buffer containing mercaptoethanol. Twenty
micrograms of the protein sample were separated on an 8%
SDS-PAGE and transferred to the nitrocellulose membrane
(GE Healthcare). LMP1 proteins were detected with mouse
anti-LMP1 monoclonal antibody (Abcam). β-actin was an
internal control and detected with rabbit anti-β-actin poly-
clonal antibody (GeneTex).
Animals
All animal experiments were approved by Institutional
Animal Care and Use Committee of National Taiwan
University College of Medicine, Taipei, Taiwan. C57BL6/
J mice (8 weeks) were obtained from the National
Laboratory Animal Center, Taipei, Taiwan.
Immunohistochemistry
Xenografts were paraffin-embedded and incubated with
mouse anti-LMP1 monoclonal antibodies (1:400, Abcam)
diluted with 5% bovine serum albumin/PBS for 12 h at
4 °C. After rinsing twice with PBS, Super Sensitive
Link-Label Immunohistochemistry Detection System
(BioGenex) was used and the specific immunostaining
was visualized with 3,3-diaminobenzidine liquid sub-
strate system (Sigma-Aldrich). All sections were coun-
terstained with hematoxylin.
In vivo tumorigenesis in C57BL6/J mice
For subcutaneous xenografts and experimental metastasis,
C57BL6/J mice were injected with LMP1-expressing TC-1
cells, subcutaneously or through tail veins, respectively. On
the 7th day after tumor inoculation, vaccination with empty
vector or LMP1/pcDNA3.1 was given. Combination with
intraperitoneal injection of cisplatin (10 mg/kg) was added
in experimental metastasis model. For tumor prevention,
mice were vaccinated 3 weeks before tumor inoculation.
Subcutaneous tumor growth was measured twice per week
and tumor volumes were estimated by modified ellipsoid
formula: (Length × Width2)/2.
Immunization of C57BL6/J mice
Empty vector or LMP1/pcDNA3.1 plasmid were coated
on to gold particles by incubating with spermidine
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(Sigma-Aldrich) on ice for 10 min. The DNA coated
gold particles were delivered to the shaved abdominal
area of the mice through a helium-driven gene gun
(BioRad Laboratories Inc.)
Flow cytometry
For detection of activated CTLs, 1 × 106 mouse splenocytes
were incubated with FITC-conjugated goat anti-mouse
CD107a antibodies (1:100, eBiosceince), and PE-conjugated
goat anti-mouse CD8 antibodies (1:100, eBioscience) on ice
for 30 min. Immunofluorescence was detected by flow
cytometry analysis (Becton-Dickinson).
Cytokine ELISArray
Mouse cytokine Multi-Analyte ELISArray was carried
out according to manufacturer’s protocol (Qiagen).
Briefly, Millipore 96-well plates (R & D system) were
incubated with mouse sera (1:4) for two hours in
room temperature. Detection antibodies were then
added and incubated for two hours in room
temperature. Avidin-HRP was added for another 1 h
under room temperature. Development solution were
then added and ELISA reader was used to detect
O.D. at 450 nm.
Interferon (INF)-γ ELISPOT assay
Millipore opaque 96-well plates (R & D system) were
incubated with RPMI-1640 for 20 min. Splenocytes
were harvested from both control or LMP1/pcDNA3.1
vaccinated mice and re-suspended with RPMI-1640
supplemented with 10% fetal bovine serum, 50 μM β-
mercaptoethanol, 100 U/ml penicillin and 100 μg/ml
streptomycin. The harvested splenocytes were counted
to the final concentration of 1 × 106 cell/well and were
incubated in 37 °C at 5% CO2 for 24 h with or without
PepMix EBV-LMP1 peptides (1 μg/ml, JPT Peptide
Technologies). Each well was triplicated. After incuba-
tion, biotinylated anti-mouse IFN-γ antibodies were
added and incubated at 4 °C for 18 h. Then,
Streptavidin-AP was added to each well and incubated
at room temperature for 2 h. Finally, BCIP/NBT
Chromogen were used for color development. The
spot forming cells (SFCs) were counted by automatically
by the ImmunoSpot Analyzer (Cellular Technology, Ltd).
Statistical analysis
Student’s t-test was used for statistical analyses. Data are
presented as mean ± S.D. and P < 0.05 is considered
statistically significant.
Results
LMP1 enhances tumor growth of TC-1 cells in vivo
To establish a LMP1-expressing tumor model which
mimics NPC, TC-1 cells were stably transfected with either
empty vector (Mock) or LMP1/pLenti6/V5-DEST (LMP1).
The expression of LMP1 was confirmed by Western blot
analysis (Fig. 1a). Next, we investigated effects of LMP1 on
tumor growth by subcutaneous injection of Mock or
LMP1-expressing TC-1 cells on C57BL6/J mice. Expres-
sions of LMP1 in Mock and LMP1 xenografts were
analyzed by immunohistochemistry (Fig. 1b). Results
showed that LMP1 expression significantly increased tumor
growth in vivo (Fig. 1c and d). Consistent with the estab-
lished oncogenic nature of LMP1 [16, 17], these results
show that ectopic LMP1 expression promotes TC-1 tumor
growth in vivo.
Vaccination of LMP1/pcDNA3.1 suppresses LMP1-expressing
tumor growth in vivo
After establishment of the LMP1-expressing tumor model,
we designed a calreticulin conjugated DNA vaccine that
encoded full-length LMP1 (LMP1/pcDNA3.1, Fig. 2a).
Next, we evaluated efficacies of LMP1 vaccine treatment
on tumor growth. C57BL6/J mice were subcutaneously
injected with LMP1-expressing TC-1 cells and then vacci-
nated weekly with empty pcDNA3.1 (control) or LMP1/
pcDNA3.1 (vaccine) for three consecutive weeks (Fig. 2b,
upper panel). Results showed that vaccination of LMP1/
pcDNA3.1 significantly suppressed LMP1-expressing
tumor growth as compared with controls (Fig. 2b, lower
panel). These results suggest that LMP1 vaccine is
effective in suppression of LMP1-expressing tumor
growth in vivo.
Vaccination of LMP1/pcDNA3.1 suppresses LMP1-expressing
tumor metastasis in vivo
To evaluate the effects of LMP1 vaccine on tumor metasta-
sis, C57BL6/J mice were injected with LMP1-expressing
TC-1 cells through tail veins and then vaccinated with or
without cisplatin weekly for 3 consecutive weeks (Fig. 3a,
upper panel). Results showed that LMP1/pcDNA3.1 vac-
cination significantly suppressed tumor metastasis as com-
pared with controls (Fig. 3b, first and second column).
Interestingly, although cisplatin alone also significantly
decreased the number of lung nodules as compared with
controls, combination of cisplatin with LMP1 vaccine was
not significantly more effective than LMP1 vaccine alone
(Fig. 3b, second and fourth column). These results indicate
that LMP1/pcDNA3.1 vaccination is effective in suppres-
sion of LMP1-expressing tumor metastasis in vivo.
Vaccination of LMP1/pcDNA3.1 prevents LMP1-expressing
tumor development in vivo
To evaluate effects of LMP1 vaccine on disease preven-
tion, three consecutive doses of vaccination were given
before subcutaneous injection of LMP1-expressing TC-1
cells (Fig. 4, upper panel). Results showed that all mice in
the control group developed tumor before the end of the
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third week. In contrast, no tumor growth was observed in
the LMP1 vaccinated group even after repeated tumor
injection on the 30th day (Fig. 4, lower panel). These
results suggest that LMP1/pcDNA3.1 vaccine is effective
in prevention of LMP1-expressing tumor growth in vivo.
LMP1/pcDNA3.1 vaccination increases activated CTLs and
induces proinflammatory cytokines in vivo
To elucidate the mechanism of tumor suppression/pre-
vention effect of LMP1/pcDNA3.1 vaccine, we examined
the population of activated CTLs in vaccinated mice.
Fig. 2 Vaccination of LMP1/pcDNA3.1 suppresses LMP1-expressing tumor growth in vivo. a LMP1/pcDNA3.1 vaccine construct. Restriction sites are as
indicated. CRT, calreticulin. b Effect of vaccination on LMP1-expressing tumor growth in vivo. Upper panel, schedule of tumor injection and vaccination.
Lower panel, tumor growth curves. *, P < 0.05. C57BL/6 J mice were subcutaneously injected with 1 × 105 LMP1-expressing TC-l cells (D0). Vaccination
with either empty pcDNA3.1 (control) or LMP1/pcDNA3.1 (vaccine) (n = 3) were given weekly on the 7th day after tumor injection for 3 consecutive
weeks. Tumor volumes were measured every 3 days and the mice were sacrificed on the fourth week
Fig. 1 LMP1 enhances tumor growth of TC-1 cells in vivo. a Western blot analysis of LMP1 expression in TC-1 cells. TC-1 cells were transfected
with either pLenti6/V5-DEST (Mock) or LMP1/pLenti6/V5-DEST (LMP1) plasmid. Stable Mock or LMP1-expressing cells were selected with blasticidin
(3 μg/ml) for 2 weeks before further experiments. β-actin was an internal control. b Immunohistochemistry of LMP1. Paraffin embedded Mock or
LMP1 xenografts were stained with anti-LMP1 antibody. Scale bar, 50 μm. c Effects of LMP1 on tumor growth in vivo. C57BL6/J mice were
subcutaneously injected with 1 × 105 of ether Mock or LMP1-expressing TC-1 cells (n = 3) and tumor sizes were measured every 5 days. *,
P < 0.05. d Images of Mock and LMP1 xenografts. Scale bar, 1 cm
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C57BL/6 J mice were vaccinated with empty vector (con-
trol) or LMP1/pcDNA3.1 (vaccine) 3 weeks before sub-
cutaneously injected with LMP1-expressing TC-1 cells
and sacrificed 2 weeks after tumor injection (Fig. 5a, upper
panel). Splenocytes were harvested for flow cytometric
analysis. Results showed that the population of CD8
+/CD107a+ cells (activated CTLs) was significantly larger
in the vaccine group as compared with the control group
(Fig. 5a, lower panel, n = 5, p < 0.01). Representative
images of flow cytometry are shown in Fig. 5b. To analyze
overall effect of LMP1 vaccine on circulating cytokines,
we collected sera from the same animals and performed
cytokine ELISArray. The results showed that significant
elevation of proinflammatory cytokines, including IL-1α,
IL-1β, IL-2, IL-6, IL-12, IL-17A, IFN-γ, TNF-α, and GM-
CSF, was observed in mice in vaccine group as compared
with mice in the control group (Fig. 5c, n = 4). These results
suggest that LMP1/pcDNA3.1 vaccination significantly
increases activated CTLs and induces proinflammatory
cytokines in vivo.
LMP1/pcDNA3.1 vaccination increases LMP1-specific T
lymphocyte activities ex vivo
To determine whether the activated CTLs in LMP1/
pcDNA3.1 vaccinated mice were LMP1-specific, we per-
formed ex vivo functional analysis using INF-γ ELISPOT
assay. Results showed that, in the presence of LMP1
peptides, the number of spot forming cells (SFCs) in the
vaccine group was significantly higher than in the con-
trol group, whereas no difference was observed between
vaccine and control groups without LMP1 peptides
stimulation (Fig. 6a, n = 5, p < 0.01). Representative
images of SFCs from control or vaccine group are shown
in Fig. 6b. These results indicate that LMP1/pcDNA3.1
vaccination successfully increases the population of
LMP1-specific T lymphocyte.
Discussion
In this study, we have established a LMP1-expressing TC-
1 xenograft model in immunocompetent C57BL6/J mice.
This tumor model allows researchers to evaluate the
efficacy of various immunotherapies against EBV LMP1-
expressing tumors such as NPC. Here, we demonstrate
Fig. 3 Vaccination of LMP1/pcDNA3.1 suppresses LMP1-expressing tumor metastasis in vivo. a Schedule of tumor injection and vaccination with
or without cisplatin. C57BL/6 J mice were intravenously injected with 1 × 105 LMP1-expressing TC-l cells (D0). On the 7th day after tumor injection,
2 μg of either empty vector (control) or LMP1/pcDNA3.1 (vaccine) was delivered to abdominal area weekly for 3 consecutive weeks. For evaluation of
combination therapy, cisplatin (10 mg/kg) was given intraperitoneally at the same time of vaccination. Mice were sacrificed on the fourth week after
tumor injection. b Number of lung nodules in each group with different treatments (n = 4). *, P < 0.05. **, P < 0.01. c Representative images of lungs
Fig. 4 Vaccination of LMP1/pcDNA3.1 prevents LMP1-expressing
tumor development in vivo. Upper panel, schedule of vaccination
and tumor injection. Lower panel, percentage (%) of mice remained
without tumor. C57BL/6 J mice were vaccinated weekly with either
empty vector (control) or LMP1/pcDNA3.1 (vaccine) (n = 10) for 3
weeks. Subcutaneous injection of 1 × 105 LMP1-expressing TC-1 cells
was given 3 weeks after the last dose of vaccination (D0). Tumor
volumes were measured every 3 days. Re-challenge of 1 × 106 LMP1-
expressing TC-1 cells was given to vaccine group on the 30th day.
No tumor growth was observed until the 80th day. **, P < 0.01
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that LMP1/pcDNA3.1 vaccination significantly suppresses
LMP1-expressing tumor growth and metastasis in vivo.
We also show that LMP1 vaccine induces a panel of pro-
inflammatory cytokines, including IL-1α, IL-1β, IL-2, IL-6,
IL-12, IL-17A, IFN-γ, TNF-α, and GM-CSF. Furthermore,
we demonstrate that LMP1 vaccine activates larger popu-
lations of LMP1-specific CTLs, indicating that LMP1
vaccine is a promising therapeutic modality.
EBV infects more than 90% of the population world-
wide [18]. After primary infection during early adoles-
cences, CTLs of the host controls, but does not
eliminate, the virus [14]. During the carcinogenesis of
NPC, EBV forms episomes in the epithelial cells and
expresses restricted viral proteins such as EBNA1,
LMP1 and LMP2 [3]. EBV develops several immune
escape mechanisms that enable the survival of malig-
nant cells harboring viral antigens. Tumor infiltrating
lymphocytes in NPC secret IL-10, which can block
CTL responses [19]. Immune recognition of EBNA1 is
restricted by its internal glycine-alanine repeat that
prevents proteasomal degradation and blocks endogenous
presentation of CTL epitopes [11, 12]. Both LMP1 and
LMP2 are able to avoid immune recognition [20, 21]. Des-
pite these hurdles, both LMP1 and LMP2 have high ex-
pression in NPC and are relatively immunogenic [22, 23],
rendering them suitable candidates for EBV-targeted
immunotherapy. In this study, we demonstrate that
LMP1-based DNA vaccine elicits LMP1-specific CTL ac-
tivities and suppresses/prevents LMP1-expressing tumor
development in murine models. This study proves our
Fig. 5 LMP1/pcDNA3.1 vaccination increases activated CTLs and induces proinflammatory cytokines in vivo. a Upper panel, schedule of vaccination and
tumor injection. Lower panel, percentages (%) of CD8+/CD107a+ cells (activated CTLs) in mice from control or vaccine groups. **, P< 0.01. C57BL/6 J mice
were vaccinated weekly with either empty pcDNA3.1 (control) or LMP1/pcDNA3.1 (vaccine) (n= 5) for 3 weeks. Subcutaneous injection of 1 × 106 LMP1-
expressing TC-1 cells was given 3 weeks after the last dose of vaccination (D0). Mice were sacrificed 2 weeks after tumor injection. Splenocytes
were harvested and subjected for flow cytometric analysis of CD8 and CD107a expression. b Representative plots of flow cytometry from control or vaccine
groups. Percentages of CD8+/CD107a+ cells (activated CTLs) are as indicated. c Statistical analysis of cytokine ELISArray. Sera from mice
in control and vaccine groups (n = 4 in each group) were collected and subjected to ELISArray. Results are presented as mean ± S.D.
*P < 0.05. **P < 0.01
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concept that LMP1 is a good candidate for targeting EBV-
associated malignancies.
It is worth mentioning that both LMP1 and LMP2
have potentials to promote oncogenic transformation
[13]. Consequently, the utility of vaccine encoding full-
length antigens in patients is limited. Although none of
the vaccinated animals in our study develop tumor on
the vaccination site (observed till 3 months after vaccin-
ation, data not shown), modification of LMP1 vaccine by
careful selection of CTL restricted epitopes will be the
subject of future study in our laboratory.
Two types of therapeutic vaccines have been evaluated
in clinical trials for NPC patients. The first type of vaccine
is transfer of autologous dendritic cells (DCs) which are
transfected with vectors containing EBV antigens ex vivo
[24, 25]. The result of a phase II trial on LMP1/LMP2-
based DC vaccine was not satisfactory because only two
out of 16 NPC patients had partial response while the rest
patients had stable or progressive disease [24]. Moreover,
broad application of DC vaccine is difficult because of the
high cost from generation of personalized DC. The second
type of vaccine is injection of vectors encoding EBV anti-
gens. In this category, LMP1 and LMP2 polyepitope
vaccines were developed by Duraiswamy et al. and were
shown to be effective in eliciting antigen specific CTL
responses and suppressing tumor growth in murine
models [7, 8]. The main difference between our study and
previous studies is that we used LMP1-expressing TC-1
cells, a murine lung epithelial cell-line [26], as target cells
instead of lymphoblasts. Being a pre-clinical study and in
the attempt to mimic NPC, epithelial models is one step
closer to resemble actual antigen processing machinery in
human NPC. Currently, a phase I clinical trial with results
of EBNA1/LMP2-based vaccine in NPC patients has been
released and antigen specific CD4 and CD8 responses
were reported [9]. Our study urges the need to incorpor-
ate LMP1 epitopes into EBV-targeted vaccine in order to
achieve utmost treatment efficacies.
We show that a panel of proinflammatory cytokines are
elevated by LMP1 vaccine treatment, including IL-1α, IL-
1β, IL-2, IL-6, IL-12, IL-17A, IFN-γ, TNF-α, and GM-CSF.
Among them, elevated IFN-γ is a strong evidence of
induced cellular immunity and CTL activities. Interestingly,
IL-10, which activates regulatory T cells and has anti-
inflammatory effect, is also elevated in LMP1 vaccinated
group. This result could be explained by previous report
that LMP1 induces CD4 cells to secret IL-10 when
processed and presented by dendritic cells [27].
Besides DNA vaccine, there are other EBV-targeted im-
munotherapies under development. The fact that EBV-
specific CTL from peripheral blood of NPC patients can be
reactivated ex vivo brings up a trend of adoptive autologous
CTL therapy [6, 28]. Although adoptive CTL therapy in
NPC gained effectiveness in phase II clinical trial [28], the
specificity of CTLs activated by EBV-transformed lympho-
blastoid cell lines (LCLs) are still under evaluation. The first
concern is that EBV-transformed LCLs preferentially stimu-
late T cells specific for EBNA antigens rather than LMP1
and LMP2 [29]. Another concern is that the sustainability
may vary by the extent of clonal expansion during ex vivo
activation [30]. In this regard, combination with LMP1/
LMP2-based DNA vaccine is another strategy to boost the
expansion of adoptively transferred EBV-specific T cells in
NPC patients.
Conclusions
Conventional concurrent chemoradiation therapy for
NPC achieves a high cure rate in localized disease [31].
However, patients with locally aggressive or metastatic
Fig. 6 LMP1/pcDNA3.1 vaccination increases LMP1-specific T
lymphocyte activities ex vivo. a INF-γ ELISPOT assay for evaluation of spot
forming cells (SFCs) from control or vaccine groups with or without
LMP1 activation. C57BL/6 J mice were vaccinated weekly with either
empty vector (control) or LMP1/pcDNA3.1 (vaccine) (n= 5) for 3 weeks.
Subcutaneous injection of 1 × 106 LMP1-expressing TC-1 cells was given
3 weeks after the last dose of vaccination. Mice were sacrificed 2 weeks
after tumor injection and splenocytes were harvested for ELISPOT assay.
Splenocytes were incubated with or without LMP1 peptides for 24 h as
indicated. **, P< 0.01. b Representative images of SFCs incubated with
LMP1 peptides from control or vaccine group
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disease continue to have a poor prognosis with a median
overall survival time of 233 days despite multiagent treat-
ment [32]. Association of NPC with EBV opens a door to
the development of EBV-targeted immunotherapy. In this
study, we proposed a novel LMP1 vaccine that augment
LMP1-specific CTL activity towards LMP1 positive
tumors. This treatment modality possesses great potentials
as adjunctive therapy for patients with recurrent/meta-
static NPC.
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